Auris's tinnitus drug misses main goals in study; shares sink

(Reuters) - Auris Medical Holding AG said its experimental drug for acute inner ear tinnitus missed the main goals of a late-stage study, sending its shares down more than 40 percent in premarket trading.

Source: Reuters: Health - August 18, 2016 Category: Consumer Health News Tags: healthNews Source Type: news